I 
109TH CONGRESS 
1ST SESSION H. R. 3168 
To amend the Public Health Service Act to provide for Centers for Clinical 
Discovery through grants from the Director of the Agency for Healthcare 
Research and Quality. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 30, 2005 
Mr. JONES of North Carolina introduced the following bill; which was referred 
to the Committee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to provide for 
Centers for Clinical Discovery through grants from the 
Director of the Agency for Healthcare Research and 
Quality. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. CENTERS FOR CLINICAL DISCOVERY. 
Part B of title IX of the Public Health Service Act 
(42 U.S.C. 299b et seq.) is amended by adding at the end 
the following section:
‘‘SEC. 918. CENTERS FOR CLINICAL DISCOVERY. 
‘‘(a) IN GENERAL.—The Director shall make grants 
on a competitive basis for research centers to accelerate 
next-generation approaches to the development of new 
therapies and diagnostics by bringing together patients, 
researchers with specialized expertise, and sophisticated 
technologies and basing such development on individual 
genotypes and individual variations in cell and molecular 
physiology. Each such center shall be known as a Center 
for Clinical Discovery. 
‘‘(b) REQUIREMENTS.—The Director may make a 
grant under subsection (a) only if, with respect to the re-
search center involved, the following conditions are met: 
‘‘(1) The application for the grant meets the re-
quirements of section 922 for approval (relating to 
technical and scientific peer review). 
‘‘(2) Such center is a collaboration between an 
academic medical center and one or more nongovern-
mental entities engaged in the development of thera-
pies and diagnostics, activities supporting such de-
velopment, and health research. 
‘‘(3) At least one the of the nongovernmental 
entities referred to in paragraph (2) has significant 
current experience in— 
‘‘(A) 
studies 
in 
pharmacogenetics, 
proteomics, metabonomics, biostatistics, clinical
chemistry, genomics, advanced imaging tech-
nology, and health registries; and 
‘‘(B) other longitudinal studies in which 
clinical and other patient data are collected to 
assist in research and development of new 
therapies and diagnostics. 
‘‘(4) The professionals serving the center in-
clude leaders in the fields of health research, health 
policy, and health-outcomes research. 
‘‘(5) The center is located at an academic med-
ical center. 
‘‘(c) INITIAL GRANT.—Not later than June 30, 2006, 
the Director shall award one grant under subsection (a), 
subject to amounts made available in appropriations Acts. 
The Director shall consider the research center involved 
as a demonstration project for purposes of such sub-
section. The Director shall evaluate the project through 
a process, and on the basis of criteria, established by the 
Director. 
‘‘(d) ADDITIONAL GRANTS.—If the research center 
operated pursuant to subsection (c) meets the criteria of 
the Director for continued support under subsection (a), 
the Director shall make grants under such subsection for 
additional centers and shall ensure, subject to amounts
made available in appropriations Acts, that not fewer than 
four research centers are operated under such subsection. 
‘‘(e) AMOUNT OF GRANT.—The amount of a grant 
under subsection (a) to any center for a fiscal year shall 
not exceed $5,000,000. 
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated $5,000,000 for fiscal year 2006, and 
$25,000,000 for each of the fiscal years 2007 through 
2011.’’. 
Æ